# Evaluating Mechanisms and Therapeutic Potential of (GLP-1R) Agonists for Glaucoma Treatment

> **NIH NIH R01** · UNIVERSITY OF PENNSYLVANIA · 2024 · $508,731

## Abstract

Project Summary
Glaucoma is characterized by retinal ganglion cell (RGC) death leading to vision loss. Available treatment
modalities continue to rely on intraocular pressure (IOP) reduction, which is insufficient to prevent progressive
neurodegeneration in a significant number of glaucoma patients. In the fight against this blinding disease,
treatment strategies that do not rely on IOP-lowering are urgently needed. In this proposal, we hypothesize that
glucagon-like peptide-1 receptor (GLP-1R) agonists protect against glaucomatous neurodegeneration by
decreasing microglia/macrophage activation and retinal macrophage infiltration, in turn preventing reactive
astrogliosis resulting in RGC rescue. This hypothesis builds upon our prior study showing that induced ocular
hypertension in a mouse model of glaucoma triggers microglia/macrophage activation and reactive astrocyte
formation in the retina. We found that treatment with the long-acting GLP-1R agonist NLY01 suppressed
microglia/macrophage activation, prevented reactive astrogliosis, and rescued RGCs following IOP elevation.
Further, our examination of insurance claims data showed that treatment with GLP-1R agonists, FDA-approved
to treat diabetes and for weight loss, is associated with decreased glaucoma risk in humans. However, the retinal
cell type(s) mediating GLP-1R agonists' RGC protection have not been identified. Further, it is not known whether
systemic macrophage infiltration and/or resident microglia transformation drive early inflammation, and whether
NLY01 modifies this response. Finally, whether this favorable response to NLY01 treatment generalizes beyond
induced IOP elevation to inherited models of chronic, progressive glaucoma is unknown. This proposal will
pursue 2 specific aims crucial to evaluating GLP-1R agonists' mechanism of action and the potential GLP-1R
agonists hold as novel glaucoma therapy: 1) Determine the mechanisms through which the GLP-1R agonist
NLY01 rescues RGCs following IOP elevation, and 2) Determine the mechanisms of GLP-1R agonist-mediated
neural rescue in an inherited model of glaucoma. Findings will determine: 1) the systemic cell type(s) facilitating
NLY01's RGC rescue, including whether macrophage infiltration drives early inflammation in response to ocular
hypertension, and 2) whether the GLP-1R agonist NLY01 exerts a long-term anti-inflammatory effect to rescue
RGCs in the DBA/2J mouse model of glaucoma. This proposal is the first step in a broader plan to disentangle
systemic effects of GLP-1R activation driving neuronal rescue. Results will serve to advance our understanding
of glaucoma pathogenesis, identify the mechanisms driving NLY01-mediated RGC rescue, and elucidate the
potential for using GLP-1R agonists in glaucoma treatment.

## Key facts

- **NIH application ID:** 10857240
- **Project number:** 5R01EY034115-02
- **Recipient organization:** UNIVERSITY OF PENNSYLVANIA
- **Principal Investigator:** Qi N Cui
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $508,731
- **Award type:** 5
- **Project period:** 2023-06-05 → 2028-04-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10857240

## Citation

> US National Institutes of Health, RePORTER application 10857240, Evaluating Mechanisms and Therapeutic Potential of (GLP-1R) Agonists for Glaucoma Treatment (5R01EY034115-02). Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/grant/nih/10857240. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*